+1 (502) 904-2126   One Westbrook Corporate Center, Suite 300, Westchester, IL 60154, USA   Site Map
ISSN: 2574 -1241

Impact Factor : 0.548

  Submit Manuscript

Mini ReviewOpen Access

Strontium Ranelate Using for the Treatment of Postmenopausal Osteoporosis

Volume 5 - Issue 4

Ahmad Oryan1, Somayeh Monazzah2 and Amin Bigham-Sadegh*3

  • Author Information Open or Close
    • 1DVM in Comparative pathology, Department of Pathology, Shiraz University, Iran
    • 2DVM Student of Veterinary Pathology, Department of Pathology, Shiraz University, Iran
    • 3DVM in Veterinary Surgery, Department of clinical Sciences, Shahrekord University, Iran

    *Corresponding author: Amin Bigham-Sadegh, DVM, DVSc, Department of Clinical Sciences, School of Veterinary Medicine, Shahrekord University, Shahrekord, Iran

Received: April 04, 2018;   Published: June 14, 2018

DOI: 10.26717/BJSTR.2018.05.001228

Full Text PDF

To view the Full Article   Peer-reviewed Article PDF


The main reason of postmenopausal osteoporosis is high bone turnover due to increased osteoclastic action. Strontium Ranelate is a new drug that is used for the treatment of postmenopausal osteoporosis. We searched PubMed in May 2016 using the terms ‘Strontium ranelate’ for experimental study and review articles. The result from the studies that we have conciliated show: Strontium ranelate enhances bone resistance and increases the bone formation. Strontium ranelate has been shown to increase bone apposition rates and bone mineral density while maintaining the quality of bone mineral; but it has no effect on mineralization. Evidence from in vitro and in vitro studies present the evidence that strontium ranelate is able to inhibit the osteoclasts resorbing activity, decreased osteoclastic differentiation (Prevention of differentiation of blood monocyte and pre-osteoclasts into osteoclasts) and increase apoptosis of osteoclasts. The studies show that strontium ranelate increased pre-osteoblastic replication and osteoblastic proliferation and differentiation as evaluated by the measurement of DNA synthesis in osteoblasts.

Strontium ranelate stimulated the synthesis of PG by human chondrocytes. Strontium ranelate promotes the synthesis of PG capable of integrating the ECM. It has been show that post fracture use of strontium ranelate on the ovariectomized rats is associated with better fracture healing as assessed by radiography, histological analysis and biomechanical testing. The exact mechanism by which strontium ranelate exerts these effects is not definitely understood, but may include inhibition of osteoclast formation and stimulation of osteoblast proliferation. In most cases use of strontium ranelate did not seem to be associated with series adverse events and most adverse events were mild and transient. It seems that Strontium ranelate is aeffective and winsome treatment for osteoporosis and in the most cases the side effect of this drug is negligible.

Abbreviations: SOTI: Spinal Osteoporosis Therapeutic Intervention; TROPOS: Treatment of Peripheral Osteoporosis; STRATOS: Strontium Ranelate for Treatment of Osteoporosis; PREVOS: Prevention of Osteoporosis

Abstract| Introduction| Material and Method| Conclusion| References|